This effect was most pronounced in MYCN non‐amplified tumors (Figure 2C), suggesting that in the context of MYCN amplification, reduced MEGF10 expression does not have a significant effect on neuroblastoma survival, presumably because the multiple biological pathways related to neuroblastoma aggressiveness that are targeted by MYCN predominate 66. The gene discussed is MYCN; the disease is neuroblastoma.